Geriatric Sexuality

  • Philip T. Zhao
  • Daniel Su
  • Allen D. SeftelEmail author


Knowledge regarding sexuality among older Americans is limited as it encompasses aspects including function, behavioral activity, partnership attitudes, and general health. As men and women grow older, they are more susceptible to medical comorbidities that can affect sexual health. Although illness and increasing age can decrease the prevalence of sexual activity, numerous studies show that a substantial number of older people engage in intercourse and other sexual behavior s even into their eighth and ninth decade of life. This chapter reviews a wide spectrum of research and clinical information related to sexual health in older men and women. Epidemiology, clinical evaluation and treatment options are discussed in detail. Other issues related to sexual health including hormone replacement therapy, sexually transmitted disease and HIV/AIDS in the geriatric population are also reviewed. Concepts of geriatric sexuality are also placed in social and cultural context with consideration of sexual orientation, personal beliefs, and other issues. This information is valuable for all urologists and others who provide healthcare for geriatric patients.


Erectile Dysfunction Testosterone Level Sexual Dysfunction Lower Urinary Tract Symptom Sexual Desire 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Fowles, DG, Greenberg S. A profile of older Americans: 2010. Administration on Aging, Department of Health and Human Services; 2010.Google Scholar
  2. 2.
    Lindau ST, Laumann EO, Levinson W, Waite LJ (2003) Synthesis of scientific disciplines in pursuit of health: the Interactive Biopsychosocial Model. Perspect Biol Med 46(Suppl 3):S74–86PubMedCentralPubMedGoogle Scholar
  3. 3.
    Laumann EO, Paik A, Rosen RC (1999) Sexual dysfunction in the United States: prevalence and predictors. JAMA 281(6):537–44PubMedGoogle Scholar
  4. 4.
    Lindau ST, Schumm P, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ (2007) A study of sexuality and health among older adults in the United States. N Engl J Med 357(8):762–74PubMedCentralPubMedGoogle Scholar
  5. 5.
    Rienzo B (1985) The impact of aging on human sexuality. J Sch Health 55(2):66–8PubMedGoogle Scholar
  6. 6.
    Lenahan P, Ellwood A (2004) Sexual health and aging. Clin Fam Pract 6(4):917–39Google Scholar
  7. 7.
    Laumann EO, Paik A, Glasser DB, Kang JH, Wang T, Levinson B, Moreira ED Jr, Nicolosi A, Gingell C (2006) A cross-national study of subjective sexual well-being among older women and men: findings from the Global Study of Sexual Attitudes and Behaviors. Arch Sex Behav 35(2):145–61PubMedGoogle Scholar
  8. 8.
    Nusbaum MRH, Gamble GR, Pathman DE (2002) Seeking medical help for sexual concerns: frequency, barriers, and missed opportunities. J Fam Pract 51:706Google Scholar
  9. 9.
    Lindau ST, Leitsch SA, Lundberg KL, Jerome J (2006) Older women’s attitudes, behavior, and communication about sex and HIV: a community-based study. J Womens Health (Larchmt) 15(6):747–53Google Scholar
  10. 10.
    Gott M, Hinchliff S, Galena E (2004) General practitioner attitudes to discussing sexual health issues with older people. Soc Sci Med 58(11):2093–103PubMedGoogle Scholar
  11. 11.
    Kaiser F (1998) Sexuality practice of geriatrics, 3rd edn. WB Saunders, Philadelphia, PA, pp 48–56Google Scholar
  12. 12.
    Ginsberg TB (2006) Aging and sexuality. Med Clin North Am 90(5):1025–36PubMedGoogle Scholar
  13. 13.
    Drench M, Losee R (1996) Sexuality and sexual capacities of elderly people. Rehabil Nurs 21(3):118–23PubMedGoogle Scholar
  14. 14.
    Jung A, Schill WB (2004) Male sexuality with advancing age. Eur J Obstet Gynecol Reprod Biol 113:123–5PubMedGoogle Scholar
  15. 15.
    Mulligan T, Reddy S, Gulur PV, Godschalk M (2003) Disorders of male sexual function. Clin Geriatr Med 19(3):473–81PubMedGoogle Scholar
  16. 16.
    Masters W, Johnson V (1981) Sex and the aging process. J Am Geriatr Soc 29:385–90PubMedGoogle Scholar
  17. 17.
    Pariser S, Niedermier J (1998) Sex and the mature woman. J Womens Health 7(7):849–59PubMedGoogle Scholar
  18. 18.
    Wilson MM (2003) Menopause. Clin Geriatr Med 19(3):483–506PubMedGoogle Scholar
  19. 19.
    West SL, D’Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM (2008) Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med 168(13):1441–9PubMedGoogle Scholar
  20. 20.
    Trompeter SE, Bettencourt R, Barrett-Connor E (2012) Sexual activity and satisfaction in healthy community-dwelling older women. Am J Med 125(1):37–43 e1PubMedCentralPubMedGoogle Scholar
  21. 21.
    Noblett KL, Ostergard DR (1999) Gynecologic disorders. Principles of geriatric medicine and gerontology, 4th edn. McGraw-Hill, New York, NY, pp 797–807Google Scholar
  22. 22.
    Robinson JG, Wallace R, Limacher M, Ren H, Cochrane B, Wassertheil-Smoller S, Ockene JK, Blanchette PL, Ko MG (2008) Cardiovascular risk in women with non-specific chest pain (from the Women’s Health Initiative Hormone Trials). Am J Cardiol 102(6):693–9PubMedGoogle Scholar
  23. 23.
    Bernstein L (2006) The risk of breast, endometrial and ovarian cancer in users of hormonal preparations. Basic Clin Pharmacol Toxicol 98(3):288–96PubMedGoogle Scholar
  24. 24.
    Johannes CB, McKinlay JB et al (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 163:460–3PubMedGoogle Scholar
  25. 25.
    McKinlay JB et al (2000) The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 12(Suppl 4):S6–11PubMedGoogle Scholar
  26. 26.
    Hogan R (1982) Influences of culture on sexuality. Nurs Clin North Am 17(3):365–76PubMedGoogle Scholar
  27. 27.
    Laumann EO et al (1994) The social organization of sexuality: sexual practices in the United States. University of Chicago Press, Chicago, IL, p. 370Google Scholar
  28. 28.
    Feldman HA et al (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54PubMedGoogle Scholar
  29. 29.
    Waldinger MD (2008) Recent advances in the classification, neurobiology and treatment of premature ejaculation. Adv Psychosom Med 29:50–69PubMedGoogle Scholar
  30. 30.
    Waldinger MD, McIntosh J, Schweitzer DH (2009) A five-nation survey to assess the distribution of the intravaginal ejaculatory latency time among the general male population. J Sex Med 6(10):2888–95PubMedGoogle Scholar
  31. 31.
    Althof SE, Abdo CH, Dean J, Hackett G, McCabe M, McMahon CG, Rosen RC, Sadovsky R, Waldinger M, Becher E, Broderick GA, Buvat J, Goldstein I, El-Meliegy AI, Giuliano F, Hellstrom WJ, Incrocci L, Jannini EA, Park K, Parish S, Porst H, Rowland D, Segraves R, Sharlip I, Simonelli C, Tan HM, International Society for Sexual Medicine (2010) International Society for Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med 7(9):2947–69PubMedGoogle Scholar
  32. 32.
    Jern P, Santtila P, Witting K, Alanko K, Harlaar N, Johansson A, von der Pahlen B, Varjonen M, Vikström N, Algars M, Sandnabba K (2007) Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of Finnish twins. J Sex Med 4(6):1739–49PubMedGoogle Scholar
  33. 33.
    Morley JE, Haren MT, Kim MJ, Kevorkian R, Perry HM (2005) Testosterone, aging and quality of life. J Endocrinol Invest 28(3 Suppl):76–80PubMedGoogle Scholar
  34. 34.
    Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, Jannini EA (2005) Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 90(12):6472–9PubMedGoogle Scholar
  35. 35.
    Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force Endocrine Society (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95(6):2536–59PubMedGoogle Scholar
  36. 36.
    Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86(2):724–31PubMedGoogle Scholar
  37. 37.
    Li JY, Li XY, Li M, Zhang GK, Ma FL, Liu ZM, Zhang NY, Meng P (2005) Decline of serum levels of free testosterone in aging healthy Chinese men. Aging Male 8(3–4):203–6PubMedGoogle Scholar
  38. 38.
    Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR (2006) Low serum testosterone and mortality in male veterans. Arch Intern Med 166(15):1660–5PubMedGoogle Scholar
  39. 39.
    Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT, EMAS Group (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363(2):123–35PubMedGoogle Scholar
  40. 40.
    Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A (2005) Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 63(4):381–94Google Scholar
  41. 41.
    Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49(6):822–30PubMedGoogle Scholar
  42. 42.
    Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11(6):319–26PubMedGoogle Scholar
  43. 43.
    Rosen RC, Catania JA, Althof SE, Pollack LM, O’Leary M, Seftel AD, Coon DW (2007) Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology 69(5):805–9PubMedGoogle Scholar
  44. 44.
    Tancredi A, Reginster JY, Schleich F, Pire G, Maassen P, Luyckx F, Legros JJ (2004) Interest of the Androgen Deficiency in Aging Males (ADAM) Questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol 151(3):355–60PubMedGoogle Scholar
  45. 45.
    Daig I, Heinemann LA, Kim S, Leungwattanakij S, Badia X, Myon E, Moore C, Saad F, Potthoff P, Thai do M (2003) The Aging Males’ Symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 1:77PubMedCentralPubMedGoogle Scholar
  46. 46.
    Rosen RC, Araujo AB, Connor MK, Gerstenberger EP, Morgentaler A, Seftel AD, Miner MM, Shabsigh R (2011) The NERI hypogonadism screener: psychometric validation in male patients and controls. Clin Endocrinol (Oxf) 74(2):248–56Google Scholar
  47. 47.
    Meston CM, Derogatis LR (2002) Validated instruments for assessing female sexual function. J Sex Marital Ther 28(Suppl 1):155–64PubMedGoogle Scholar
  48. 48.
    Wiegel M, Meston C, Rosen R (2005) The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther 31(1):1–20PubMedGoogle Scholar
  49. 49.
    Baser RE, Li Y, Carter J (2012) Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors. Cancer 118(18):4606–18PubMedGoogle Scholar
  50. 50.
    Gerstenberger EP, Rosen RC, Brewer JV, Meston CM, Brotto LA, Wiegel M, Sand M (2010) Sexual desire and the female sexual function index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder. J Sex Med 7(9):3096–103PubMedGoogle Scholar
  51. 51.
    Impotence (1993) NIH consensus development panel on impotence. JAMA 270(1):83–90Google Scholar
  52. 52.
    Seftel A, Miner M, Kloner R, Althof S (2007) Office evaluation of male sexual dysfunction. Urol Clin North Am 34(4):463–82PubMedGoogle Scholar
  53. 53.
    Miner M, Seftel AD (2007) Centrally acting mechanisms for the treatment of male sexual dysfunction. Urol Clin North Am 34(4):483–96PubMedGoogle Scholar
  54. 54.
    Lue TF (2000) Erectile dysfunction. N Engl J Med 342:1802–13PubMedGoogle Scholar
  55. 55.
    de Tejada IS, Goldstein I, Azadzoi K, Krane RJ, Cohen RA (1989) Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 320:1025–30Google Scholar
  56. 56.
    Rajfer J et al (1992) Nitric oxide as a mediator of relaxation of the corpus cavernosum. N Engl J Med 326:1638Google Scholar
  57. 57.
    Bancroft J (2005) The endocrinology of sexual arousal. J Endocrinol 186:411–27PubMedGoogle Scholar
  58. 58.
    Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U, Jonas U (2001) Cavernous and systemic testosterone plasma levels during different penile conditions in healthy males and patients with erectile dysfunction. Urology 58(3):435–40PubMedGoogle Scholar
  59. 59.
    Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I (1999) Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 140(4):1861–8PubMedGoogle Scholar
  60. 60.
    Zvara P, Sioufi R, Schipper HM, Begin LR, Brock GB (1995) Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Int J Impot Res 7(4):209–19PubMedGoogle Scholar
  61. 61.
    Reilly CM, Lewis RW, Stopper VS, Mills TM (1997) Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway. J Androl 18(6):588–94PubMedGoogle Scholar
  62. 62.
    Hall R, Andrews PL, Hoyle CH (2002) Effects of testosterone on neuromuscular transmission in rat isolated urinary bladder. Eur J Pharmacol 449(3):301–9PubMedGoogle Scholar
  63. 63.
    Morley JE, Kaiser FE, Perry HM III, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ (1997) Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46(4):410–3PubMedGoogle Scholar
  64. 64.
    Haren MT, Kim MJ, Tariq SH, Wittert GA, Morley JE (2006) Andropause: a quality-of-life issue in older males. Med Clin North Am 90(5):1005–23PubMedGoogle Scholar
  65. 65.
    Marcell TJ, Harman SM, Urban RJ, Metz DD, Rodgers BD, Blackman MR (2001) Comparison of GH, IGF-I, and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men. Am J Physiol Endocrinol Metab 281(6):E1159–64PubMedGoogle Scholar
  66. 66.
    Benito M, Vasilic B, Wehrli FW, Bunker B, Wald M, Gomberg B, Wright AC, Zemel B, Cucchiara A, Snyder PJ (2005) Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res 20(10):1785–91PubMedGoogle Scholar
  67. 67.
    Dacal K, Sereika SM, Greenspan SL (2006) Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 54(1):85–90PubMedGoogle Scholar
  68. 68.
    Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM (2002) Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 87(11):5001–7PubMedGoogle Scholar
  69. 69.
    Dunajska K, Milewicz A, Szymczak J, Jêdrzejuk D, Kuliczkowski W, Salomon P, Nowicki P (2004) Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. Aging Male 7(3):197–204PubMedGoogle Scholar
  70. 70.
    Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT (2004) Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 109(17):2074–9PubMedGoogle Scholar
  71. 71.
    Lish KM, Steeds RP, Jones TH, Diver MJ, Channer KS (2000) Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 102(16):1906–11Google Scholar
  72. 72.
    Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS (2004) Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90(8):871–6PubMedCentralPubMedGoogle Scholar
  73. 73.
    Bhasin S, Cunningham GR, Hayes FJ (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536–59PubMedGoogle Scholar
  74. 74.
    Vesper HW, Botelho JC, Shacklady C et al (2008) CDC project on standardizing steroid 380 hormone measurements. Steroids 73:1286–92PubMedGoogle Scholar
  75. 75.
    Wang C, Nieschlag E, Swerdloff R et al (2009) Investigation, treatment, and monitoring of 385 late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA 386 recommendations. J Androl 30(1–9):387Google Scholar
  76. 76.
    Institute of Medicine. Testosterone and aging: clinical research directions. 2003.Google Scholar
  77. 77.
  78. 78.
    Davis SR, Davison SL, Donath S, Bell RJ (2005) Circulating androgen levels and self-reported sexual function in women. JAMA 294(1):91–6PubMedGoogle Scholar
  79. 79.
    Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N (2006) Androgen therapy in women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 91(10):3697–710PubMedGoogle Scholar
  80. 80.
    Tomaselli KP. Intrinsa stalled by concerns about safety.
  81. 81.
  82. 82.
  83. 83.
    Stefanick M, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295(14):1647–57PubMedGoogle Scholar
  84. 84.
    Buster JE (2010) Transdermal menopausal hormone therapy: delivery through skin changes the rules. Expert Opin Pharmacother 11(9):1489–99PubMedGoogle Scholar
  85. 85.
    Liebergall-Wischnitzer M, Paltiel O, Hochner Celnikier D, Lavy Y, Manor O, Woloski Wruble AC (2012) Sexual function and quality of life of women with stress urinary incontinence: a randomized controlled trial comparing the Paula Method (circular muscle exercises) to pelvic floor muscle training (PFMT) exercises. J Sex Med 9(6):1613–23PubMedGoogle Scholar
  86. 86.
    Filocamo MT, Serati M, Frumenzio E, Li Marzi V, Cattoni E, Champagne A, Salvatore S, Nicita G, Costantini E (2011) The impact of mid-urethral slings for the treatment of urodynamic stress incontinence on female sexual function: a multicenter prospective study. J Sex Med 8(7):2002–8PubMedGoogle Scholar
  87. 87.
    Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT, Garritty C, Soares-Weiser K, Daniel R, Sampson M, Fox S, Moher D, Wilt TJ (2009) Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 151(9):650–61PubMedGoogle Scholar
  88. 88.
    Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338(20):1397–404PubMedGoogle Scholar
  89. 89.
    Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168(4 Pt 1):1332–6PubMedGoogle Scholar
  90. 90.
    Hatzimouratidis K, Hatzichristou DG (2009) Phosphodiesterase type 5 inhibitors: unmet needs. Curr Pharm Des 15(30):3476–85PubMedGoogle Scholar
  91. 91.
    Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ (2002) Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 162(12):1349–60PubMedGoogle Scholar
  92. 92.
    Wagner G, Montorsi F, Auerbach S, Collins M (2001) Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 56(2):M113–9PubMedGoogle Scholar
  93. 93.
    Richter S, Vardi Y, Ringel A, Shalev M, Nissenkorn I (2001) Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men. Int J Impot Res 13(3):172–5PubMedGoogle Scholar
  94. 94.
    Al-Najar A, Naumann CM, Kaufmann S, Steinbach-Jensch A, Hamann MF, Jünemann KP, van der Horst C (2009) Should being aged over 70 years hinder penile prosthesis implantation? BJU Int 104(6):834–7PubMedGoogle Scholar
  95. 95.
    Conaglen HM, Conaglen JV (2008) Investigating women’s preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners’ preference study. J Sex Med 5(5):1198–207PubMedGoogle Scholar
  96. 96.
    Althof SE, Rubio-Aurioles E, Kingsberg S, Zeigler H, Wong DG, Burns P (2010) Impact of tadalafil once daily in men with erectile dysfunction–including a report of the partners’ evaluation. Urology 75(6):1358–63PubMedGoogle Scholar
  97. 97.
    Rajfer J, Aliotta PJ, Steidle CP, Fitch WP III, Zhao Y, Yu A (2007) Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 19(1):95–103PubMedGoogle Scholar
  98. 98.
    Seftel AD, Buvat J, Althof SE, McMurray JG, Zeigler HL, Burns PR, Wong DG (2009) Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. Int J Impot Res 21(4):240–8PubMedGoogle Scholar
  99. 99.
    Abrams P (1995) Managing lower urinary tract symptoms in older men. Br Med J 310:1113–7Google Scholar
  100. 100.
    Lepor H, Kazzazi A, Djavan B (2012) α-Blockers for benign prostatic hyperplasia: the new era. Curr Opin Urol 22(1):7–15PubMedGoogle Scholar
  101. 101.
    Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U (2000) Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 12(6):305–11PubMedGoogle Scholar
  102. 102.
    Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O’Leary MP, Puppo P, Robertson C, Giuliano F (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44(6):637–49PubMedGoogle Scholar
  103. 103.
    Mouli S, McVary KT (2009) PDE5 inhibitors for LUTS. Prostate Cancer Prostatic Dis 12(4):316–24PubMedGoogle Scholar
  104. 104.
    Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P (2006) Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49(4):740–5PubMedGoogle Scholar
  105. 105.
    Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M (2004) Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145(Feb 5):2253–63PubMedGoogle Scholar
  106. 106.
    Zhang X, Zang N, Wei Y, Yin J, Teng R, Seftel A, Disanto ME (2012) Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. Am J Physiol Endocrinol Metab 302(2):E243–53PubMedCentralPubMedGoogle Scholar
  107. 107.
    Uckert S, Sormes M, Kedia G, Scheller F, Knapp WH, Jonas U, Stief CG (2008) Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 71(3):526–30PubMedGoogle Scholar
  108. 108.
    FDA News Release: FDA approves cialis to treat benign prostatic hyperplasia.
  109. 109.
    Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61(5):917–25PubMedGoogle Scholar
  110. 110.
    Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ (2012) Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 9(1):271–81PubMedGoogle Scholar
  111. 111.
    Seftel AD, Mack RJ, Secrest AR, Smith TM (2004) Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl 25(6):963–72PubMedGoogle Scholar
  112. 112.
    Donatucci CF, Brock GB, Goldfischer ER, Pommerville PJ, Elion-Mboussa A, Kissel JD, Viktrup L (2011) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int 107(7):1110–6PubMedGoogle Scholar
  113. 113.
    McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177(3):1071–7PubMedGoogle Scholar
  114. 114.
    Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, Vignozzi L, Serni S, Maggi M, Carini M (2012) A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 9(6):1624–33PubMedGoogle Scholar
  115. 115.
    Lunenfeld B, Saad F, Hoesl CE (2005) ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male 8(2):59–74PubMedGoogle Scholar
  116. 116.
    Haren M, Chapman I, Coates P, Morley J, Wittert G (2005) Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age Ageing 34(2):125–30PubMedGoogle Scholar
  117. 117.
    Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS (2002) The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab 87(4):1467–72PubMedGoogle Scholar
  118. 118.
    Shabsigh R (2005) Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2(6):785–92PubMedGoogle Scholar
  119. 119.
    Shabsigh R (2003) Hypogonadism and erectile dysfunction: the role for testosterone therapy. Int J Impot Res 15(Suppl 4):S9–13, ReviewPubMedGoogle Scholar
  120. 120.
    Tariq SH, Haleem U, Omran ML, Kaiser FE, Perry HM III, Morley JE (2003) Erectile dysfunction: etiology and treatment in young and old patients. Clin Geriatr Med 19(3):539–51PubMedGoogle Scholar
  121. 121.
    Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A (2003) Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 58(5):632–8Google Scholar
  122. 122.
    Jain P, Rademaker AW, McVary KT (2000) Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 164(2):371–5PubMedGoogle Scholar
  123. 123.
    Testosterone topical solution (Axiron) for hypogonadism. Med Lett Drugs Ther. 2011;53(1368):54–5.Google Scholar
  124. 124.
    Kaufman JM, Miller MG, Fitzpatrick S, McWhirter C, Brennan JJ (2012) One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study. J Sex Med 9(4):1149–61PubMedGoogle Scholar
  125. 125.
    Seftel A (2007) Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res 19(1):2–24PubMedGoogle Scholar
  126. 126.
  127. 127.
    Morgentaler A (2011) Testosterone and prostate cancer: what are the risks for middle-aged men? Urol Clin North Am 38(2):119–24PubMedGoogle Scholar
  128. 128.
    Basaria S, Coviello A et al (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–22PubMedCentralPubMedGoogle Scholar
  129. 129.
    Dandona P, Dhindsa S (2011) Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 96(9):2643–51PubMedCentralPubMedGoogle Scholar
  130. 130.
    Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M (2011) Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 8(1):272–83PubMedGoogle Scholar
  131. 131.
    Porst H (2011) An overview of pharmacotherapy in premature ejaculation. J Sex Med 8(Suppl 4):335–41PubMedGoogle Scholar
  132. 132.
    Melnik T, Althof S, Atallah AN, Puga ME, Glina S, Riera R (2011) Psychosocial interventions for premature ejaculation. Cochrane Database Syst Rev 8, CD008195PubMedGoogle Scholar
  133. 133.
    McMahon CG (2010) Dapoxetine for premature ejaculation. Expert Opin Pharmacother 11(10):1741–52PubMedGoogle Scholar
  134. 134.
    National Center of Health Statistics. US Department of Health and Human Services Centers for Disease Control and Prevention. AIDS diagnoses by age. 2009. Accessed 2011.
  135. 135.
    Centers of Disease Control and Prevention, United States. AIDS among persons aged >50 years. 2009. Accessed 2011.
  136. 136.
    Senior K (2005) Growing old with HIV. Lancet 5:739Google Scholar
  137. 137.
    Wilson MM (2003) Sexually transmitted diseases. Clin Geriatr Med 19:637–55PubMedGoogle Scholar
  138. 138.
    Kaiser F (2003) Sexual function and the older woman. Clin Geriatr Med 19(3):463–72PubMedGoogle Scholar
  139. 139.
    Levine GN, Steinke EE, Bakaeen FG, Bozkurt B, Cheitlin MD, Conti JB, Foster E, Jaarsma T, Kloner RA, Lange RA, Lindau ST, Maron BJ, Moser DK, Ohman EM, Seftel AD, Stewart WJ, American Heart Association Council on Clinical Cardiology, Council on Cardiovascular Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research (2012) Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 125(8):1058–72PubMedGoogle Scholar
  140. 140.
    Morley JE, Kaiser FE (2003) Female sexuality. Med Clin North Am 87:1077–90PubMedGoogle Scholar
  141. 141.
    Goetsch M (2005) The effect of total hysterectomy on specific sexual sensations. Am J Obstet Gynecol 192:1922–7PubMedGoogle Scholar
  142. 142.
    Anastasiou I, Yiannopoulou KG, Mihalakis A, Hatziandonakis N, Constantinides C (2011) Symptoms of acute posttraumatic stress disorder in prostate cancer patients following radical prostatectomy. Am J Mens Health 5(1):84–9PubMedGoogle Scholar
  143. 143.
    MacDonald R, Fink HA, Huckabay C, Monga M, Wilt TJ (2007) Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness. BJU Int 100(1):76–81PubMedGoogle Scholar
  144. 144.
    Lee CT, Yeh CJ, Lee MC, Lin HS, Chen VC, Hsieh MH, Yen CH, Lai TJ (2012) Leisure activity, mobility limitation and stress as modifiable risk factors for depressive symptoms in the elderly: results of a national longitudinal study. Arch Gerontol Geriatr 54(2):e221–9PubMedGoogle Scholar
  145. 145.
    Kingsberg SA, Althof SE (2011) Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction. J Sex Med 8(12):3262–70PubMedGoogle Scholar
  146. 146.
    Kingsberg SA (2002) The impact of aging on sexual function in women and their partners. Arch Sex Behav 31(5):431–7PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Rutgers Robert Wood Johnson Medical SchoolNew BrunswickUSA
  2. 2.Division of UrologyRutgers Robert Wood Johnson Medical SchoolNew BrunswickUSA
  3. 3.Division of Urology, Department of SurgeryCooper University Health Care, Cooper Medical School of Rowan UniversityMarltonUSA

Personalised recommendations